Introduction

Low grade inflammation provoked by immune cells contributes to insulin resistance, a major cause of Type 2 diabetes [1,2]. In obesity, macrophage infiltration of the expanding adipose tissue renders adipocytes insulin-resistant, consequently elevating circulating fatty acids and inflammatory cytokines that in turn contribute to insulin resistance in skeletal muscle [3,4,5,6]. While the participation of macrophages in triggering adipose tissue insulin resistance is well established [3,7,8], it is less clear whether and how macrophage-derived factors affect skeletal muscle.

Recent studies demonstrate the presence of proinflammatory macrophages infiltrating muscle tissue, whether abutting the skeletal muscle fibres directly or surrounding muscle-infiltrating adipocytes in the context of obesity [4,5,6,9]. Cytokines released by local pro-inflammatory macrophages might directly affect muscle insulin action. Alternatively or concomitantly, cytokines produced by pro-inflammatory macrophages in the expanding adipose tissue may reach muscle in an endocrine fashion (via the circulation) to render it resistant to insulin. There is growing evidence that fatty acids trigger macrophages to secrete factors that impair insulin action [5,10]. In this context, we and others...
have shown that fatty acids activate macrophages to release cytokines that cause insulin resistance in adipocytes and muscle cells [3,5,10,11]. As proof of concept, we recently reported that conditioned medium from palmitate-treated macrophages (CM-PA) provokes insulin resistance in muscle cells at the levels of Akt signalling, glucose transporter 4 (GLUT4) translocation and glucose uptake [11], but how CM-PA confers this negative response onto muscle cells is yet unknown.

In addition to the cytokine-associated insulin resistance, the most abundant dietary saturated fatty acid palmitate can directly impair insulin signalling in muscle cells, reducing their insulin-dependent gain in surface GLUT4 and glucose uptake [12,13,14]. Several mechanisms have been proposed for the generation of palmitate-induced muscle insulin resistance, in particular the involvement of diacylglycerol (DAG)-sensitive novel protein kinase C's (PKCα, PKCe, PKCδ, and PKCγ) [15,16,17]. Palmitate and other fatty acids activate novel PKC's in skeletal muscle [16,18,19], thereby curbing downstream insulin signalling [15,20,21]. PKCδ can directly phosphorylate serine residues on Insulin Receptor Substrate-1 (IRS1) [20], and both PKCδ and PKCe also act upstream of the c-jun N-terminal kinase (JNK) to inhibit insulin signalling through this inflammatory stress kinase [22,23,24]. In addition, PKCe can phosphorylate the insulin receptor to reduce insulin action [25,26]. Notably, PKCδ and PKCe also activate nuclear factor kappa B (NF-kB)-dependent pathways in muscle cells to promote expression of proinflammatory cytokines and chemokines, major mediators of inflammation-induced insulin resistance [16,18]. Hence, novel PKC's intersect the muscle cell autonomous inflammatory response.

Given that both macrophage-derived factors and saturated fatty acids cause insulin resistance and activate muscle inflammatory pathways, and that fatty acids engage novel PKC's in this response, we hypothesized that this PKC family may represent a unifying pathway of pro-inflammatory pathways and increased expression of other fatty acids activate novel PKC's in skeletal muscle [3,5,10,11]. As proof of concept, we recently reported that CM-PA activates PKCδ and PKCe inhibition of diacylglycerol (DAG)-sensitive novel protein kinase C's (PKCα, PKCe, PKCδ, and PKCγ) [15,16,17]. Palmitate and other fatty acids activate novel PKC's in skeletal muscle [16,18,19], thereby curbing downstream insulin signalling [15,20,21]. PKCδ can directly phosphorylate serine residues on Insulin Receptor Substrate-1 (IRS1) [20], and both PKCδ and PKCe also act upstream of the c-jun N-terminal kinase (JNK) to inhibit insulin signalling through this inflammatory stress kinase [22,23,24]. In addition, PKCe can phosphorylate the insulin receptor to reduce insulin action [25,26]. Notably, PKCδ and PKCe also activate nuclear factor kappa B (NF-kB)-dependent pathways in muscle cells to promote expression of proinflammatory cytokines and chemokines, major mediators of inflammation-induced insulin resistance [16,18]. Hence, novel PKC's intersect the muscle cell autonomous inflammatory response.

Given that both macrophage-derived factors and saturated fatty acids cause insulin resistance and activate muscle inflammatory pathways, and that fatty acids engage novel PKC's in this response, we hypothesized that this PKC family may represent a unifying sensor of dietary and inflammatory signals, that when activated would interfere with insulin action. Supporting this hypothesis, we report that CM-PA activates PKCδ and ε to induce insulin resistance at the levels of IRS1, Akt Substrate of 160 kDa (AS160), GLUT4 translocation and glucose uptake, along with the induction of pro-inflammatory pathways and increased expression of inflammatory cytokines within muscle cells. The results support the possibility that, in vitro, the ability of palmitate to induce insulin resistance may include activating macrophages to secrete proinflammatory cytokines and chemokines that would negatively impact on insulin action in skeletal muscle, acting through novel PKC's.

**Materials and Methods**

**Materials and Reagents**

Antibodies to phospho Akt (Ser473), phospho-AS160, phospho-JNK (Thr183/Tyr185), phospho-p70S6K (Thr389), phospho-IRS1 (Ser307), monoclonal anti-phosphotyrosine (PY99), antibodies to the insulin receptor, insulin receptor substrate (IRS)-1, phospho-IRS1 (Ser307), phospho-PKCe (Ser729), anti-histone and polyclonal anti-porcine antibody were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). PKC inhibitors Go6983 and Go6976 were from Calbiochem (San Diego, CA). Predesigned rat siPKCδ (5′-AACCTCAAGGGC-GAATGTCAAA-3′), siPKCe (5′-CAGATGAGTCTCTGACTGAT-3′) and non-related siRNA (siNR) (5′-ATAAGGGTAC-3′) were from Qiagen (Mississauga, Ontario, Canada). Human insulin (Humulin R) was from Eli Lilly Canada (Toronto, Ontario, Canada). Cytochalasin B, 2-deoxyglucose (2-DG), protease inhibitor cocktail, monoclonal antiactinin-1, and other chemicals unless otherwise noted were from Sigma Chemical (St. Louis, MO), 2-Deoxy-D-[3H] glucose was from PerkinElmer (Boston, MA). The RNAeasy Mini kit was from Qiagen (Mississauga, Ontario, Canada). The SuperScript® VILO™ cDNA Synthesis Kit was from Invitrogen (Burlington, Ontario, Canada). Reagents for quantitative PCR analysis were from Applied Biosystems (Carlsbad, CA). This includes Fast Advanced master mix and Taqman assays for detection of Hprt1 (Assay ID: Rn01527840_m1), tumor necrosis factor α (TNF-α, Rn00562055_m1), interleukin 6 (IL-6, Rn01113390_m1), Pgc2 (50X2, Rn01439929_m1) and C02 (MCP1, Rn00830553_m1) transcripts. The Proteome Profiler Mouse Cytokine Array Kit, Panel A and recombinant mouse cytokines/chemokines (CXCL1, CXCL2, CXCL10 and TNFα) were from RnD Systems (Minneapolis, MN).

L6-GLUT4/myc myoblast cell lines and treatments

L6-GLUT4/myc myoblasts [27] without or with stable expression of the Akt substrate AS160 (L6-GLUT4/myc-AS160) cells or of the insulin receptor (L6-GLUT4/myc-IR) cells, as indicated, were cultured in α-MEM supplemented with 10% FBS, blasticidin S (2 μg/ml), and 1% antibiotic/antimycotic solution (10,000 U/ml penicillin G, 10 mg/ml streptomycin, and 25 μg/ml amphotericin B) under 5% CO₂ at 37°C. Myoblast cultures were typically treated with the indicated macrophage-conditioned media (CM) or exogenous cytokines for the times indicated, serum-deprived for 3 h and stimulated with insulin (100 nM, 20 min). Where listed, Go6983 (1 μM), or Go6976 (1 μM) were used to inhibit PKC's.

Macrophage treatment with palmitate and collection of conditioned media (CM)

RAW 264.7 macrophages [purchased from American Type Culture Collection, Manassas, VA, USA, Catalogue No TIB-71] were grown in α-MEM supplemented with 1% antibiotic/antimycotic and 10% fetal bovine serum. A 5 mM palmitate-10% BSA stock solution was prepared as described [12]. Macrophages were treated with BSA alone or 500 μM conjugated palmitate/1% BSA in culture medium for 6 h, then washed several times with PBS, and fresh medium was added. After 12 h, conditioned media (CM-BSA, CM-PA) were collected, centrifuged (7 min, 3,500 rpm), and added to L6-GLUT4/myc myoblast cultures for 1 h or 24 h. Given the intermediate washes, no residual palmitate is expected to be present in CM-PA. Following the 1 h or 24 h incubation, cells were washed twice with 0.5 ml PBS and lysed in the appropriate ice-cold lysis buffer. Cell lysates were used for immunoblotting, immunoprecipitation and gene expression analysis.

RT-PCR and small interfering RNA (siRNA)-mediated PKC knockdown

For quantitative PCR (qPCR), RNA was isolated with the RNAeasy Mini kit and used to generate cDNA using the SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen). qPCR was performed using Fast Advanced master mix (Applied Biosystems) and Taqman assays for rat TNFα, IL6, monocyte chemotactic protein 1 (MCP-1) and cyclooxygenase 2 (COX-2) according to the manufacturer’s instructions. The input of cDNA was 10 ng/reaction. qRT-PCR was performed at 50°C/2 min, 95°C/20 sec followed by 40 cycles of 95°C/1 sec and 60°C/20 sec. Comparative cycle threshold results expressed relative to hprt1 were used. For PKCδ and PKCe knockdown, L6GLUT4/myc myoblasts were treated with 100 nM siRNA to PKCδ (PKCδ siRNA) (AAGCTCAGGCGAATGTCAAA) or siRNA to PKCe (PKCe siRNA) (CGATGTACGATCCTGACTGAT) or
a combination of both at 100 nM each using lipofectamine RNAi-max reagent (Invitrogen).

**Immunoblotting and immunoprecipitation**

Confluent L6-GLUT4myc myoblasts in 10 cm diameter dishes were treated as indicated and immediately processed for SDS-PAGE and immunoblotting as described [28]. IRS1 in cell lysates was immunoprecipitated using an anti-IRS1 antibody. The immunocomplex and the supernatant were resuspended in Laemmli buffer and heated for 5 min at 95°C. The immunocomplex was separated into two equal portions, separated by SDS-PAGE and immunoblotted with anti-phosphotyrosine, antiphospho-IRS1 (Ser307) or antiphospho-IRS1 (Ser1101), and anti-IRS1.

**Nuclear localization of Nuclear Factor-Kappa B (NF-κB)**

A nuclear extract kit (Active Motif, CA) was used to obtain cytosolic and nuclear fractions from L6 myoblasts. Briefly, after treatments, cells were scraped and centrifuged for 5 min at 500 rpm at 4°C, resuspended in hypotonic 1 × buffer and detergent-extracted. The suspension was centrifuged for 30 s at 14,000 g at 4°C, yielding the cytoplasmic fraction in the supernatant and a nuclear pellet that was re-purified. Samples were analyzed for phosphorylated or total NF-κB A/p65 (1:1000).

2-deoxy-[3H]glucose uptake and cell surface GLUT4myc

L6-GLUT4myc myoblasts grown in 24-well plates and serum-deprived for 3–5 h, then treated with or without insulin (100 nM, 20 min). 2-Deoxyglucose uptake was measured as described [29], and cell surface GLUT4myc was measured as described [27,29].

**Cytokine and chemokine determination and treatment**

CM-PA & CM-BSA were analyzed for multiple cytokines and chemokines by ProtimeProfiler Mouse Cytokine Array (RnD Systems) according to the manufacturer’s instructions for cell culture supernatants. Membranes were exposed to autoradiography film for 1 s, 30 s or 2 min. Protein spots were quantified using ImageJ software (NIH, USA). To examine the impact of cytokines and chemokines on activation of PKCθ and ε, myoblasts were incubated with cytokines and chemokines (0–100 ng/ml) individually or in combination, for 24 h. Subsequently cells were washed and lysed in the appropriate ice-cold lysis buffer prior to immunoblotting.

**Measurement of non-esterified fatty acids (NEFAs) in media**

NEFA levels were measured according to the ACS.ACOD (Acyl CoA synthase - Acyl CoA oxidase) method using the HR series NEFA-HR kit No. 999-34691 (Wako Pure Chemical Industries, Osaka, Japan).

**Statistical analysis**

Values are means ± SE. Wherever appropriate, one-way ANOVA followed by Tukey or Bonferroni tests was used to determine differences between group mean values. The level of statistical significance was set at P<0.05.

**Results**

CM-PA increases IRS1 serine phosphorylation and reduces its tyrosine phosphorylation in response to insulin

We have previously reported a drop in insulin-stimulated phosphorylation of Akt on Ser473 in L6 myoblasts treated with ceramides as a model of lipotoxicity [30] or with conditioned medium from palmitate-treated macrophages (CM-PA) as a model of inflammatory toxicity [11]. The ceramide effect was not accompanied by upstream signalling defects at the level of IRS1, the substrate of the insulin receptor relevant for GLUT4 traffic [31]. However, a defect at this first step in insulin action is often observed in conditions of in vivo insulin resistance. Hence we first assessed whether macrophage-conditioned media alters insulin signalling at the level of IRS1. In myoblasts incubated with medium from untreated macrophages (regular medium, RM) or CM-BSA, insulin increased tyrosine phosphorylation of IRS1 by approximately 2 fold (Fig. 1A). On the other hand, in myoblasts treated with CM-PA, insulin-stimulated tyrosine phosphorylation of IRS1 was significantly reduced (45±6%, Fig. 1A). No change in IRS1 tyrosine phosphorylation was observed in the absence of insulin. Phosphorylation of IRS1 on selective serine residues can reduce its tyrosine phosphorylation in response to insulin [32]. Indeed, when compared with CM-BSA, CM-PA significantly increased myoblast IRS1 phosphorylation at serine 307 and 1101 (1.7±0.2-fold vs CM-BSA and 1.6±0.1-fold vs CM-BSA, Fig. 1B and 1C).

CM-PA activates novel PKCθ and PKCe in L6 myoblasts

Pro-inflammatory cytokines and chemokines activate PKCθ and ε [33,34], and these kinases can lead to IRS1 serine phosphorylation thereby reducing its tyrosine phosphorylation and downstream activation of Akt [15,20,21]. Since we have observed elevated levels of the cytokine TNFα in CM-PA [11], we next explored whether CM-PA activates novel PKC’s in myoblasts. PKCθ is activated by phosphorylation of Thr530 in its activation loop, and PKCe through phosphorylation of Ser729 within its carboxyl-terminal hydrophobic site [35,36,37,38]. We found that while incubating myoblasts for 24 h with RM or CM-BSA had no effect on either PKC phosphorylation, CM-PA caused an approximate 1.6-fold rise in each PKCθ Thr530 and PKCe Ser729 phosphorylation, without changing either PKC protein content (Fig. 2A and 2B). Of note, incubating myoblasts with CM-BSA or CM-PA for an acute period of 1 h had no effect on either PKC phosphorylation (Fig. S1). To verify if the CM-PA-induced PKCθ and PKCe activation influenced insulin signalling, we first used the novel and conventional PKC inhibitor Go6983 and the conventional PKC inhibitor Go6976. Go6976 had no effect on myoblast PKCθ or PKCe phosphorylation in unchallenged cells (data not shown). In the presence of CM-PA, Go69693 abrogated the increase in PKCθ and PKCe phosphorylation (Fig. 2C and Fig. 2D). As expected, Go6976 did not alter the CM-PA-induced PKCθ or PKCe activation (Fig. 2E and 2F).

Inhibition of novel PKC’s prevents the reduction in insulin-dependent IRS1 tyrosine phosphorylation provoked by CM-PA

Phosphorylation of IRS1 at a number of susceptible serine residues lowers insulin signalling by reducing its insulin-stimulated tyrosine phosphorylation. In particular, PKCθ can directly induce phosphorylation of IRS1 at serine 1101 in muscle [20]. There is no known, direct PKCε-dependent IRS1 phosphorylation although both PKCθ and PKCe can affect IRS1 acting through JNK [22,23,24], and PKCe can modulate insulin receptor function and attenuate downstream insulin signalling [25,26]. Given that CM-PA activated both PKC’s, we investigated whether the deleterious actions of CM-PA on IRS1 were averted by the novel and conventional PKC inhibitor Go6983. Indeed, Go6983 abrogated the CM-PA-induced increase in phosphorylation of insulin-dependent IRS1 tyrosine phosphorylation.
IRS1 at Ser1101 without change in the total content of IRS1 (Fig. 3A). In contrast, although CM-PA reduced the insulin dependent tyrosine phosphorylation of the insulin receptor, this response was not restored by G6983 (Fig. S2). We previously documented an increase in c-jun N-terminal kinase (JNK) phosphorylation in myoblasts treated with CM-PA [11]. As both PKC\(^\text{h}\) and PKC\(^\text{e}\) can also act via JNK to increase IRS1 phosphorylation at Ser307 [22,23,24], we assessed whether novel PKC inhibition prevented CM-PA-induced JNK and IRS1 Ser307 phosphorylation. Indeed, myoblast treatment with G6983 markedly reduced both these effects of CM-PA, without changing the total JNK or IRS1 content (Fig. 3B and 3C). Importantly, the G6983-induced loss of IRS1 serine phosphorylation was accompanied by restoration of insulin induced IRS1 tyrosine phosphorylation (Fig. 3D). Of note, the conventional PKC inhibitor G6976 failed to restore the CM-PA-mediated drop in IRS1 tyrosine phosphorylation (data not shown). These results suggest that the effects on IRS1 caused by CM-PA are mediated through its activation of PKC\(^\text{h}\) and PKC\(^\text{e}\).

G6983 reverses the drop in insulin-stimulated Akt and AS160 phosphorylation evoked by CM-PA

Downstream of IRS1, phosphoinositide 3-kinase (PI3K) activates Akt that in turn phosphorylates the RAB-GAP AS160, to allow activation of Rabs 8A and 13 that are essential for GLUT4 translocation in muscle cells [39]. Exposing myoblasts to CM-PA for 24 h reduced insulin-stimulated phosphorylation of Akt on Ser473 (Fig. 4A) and importantly caused a more robust drop in AS160 phosphorylation, signifying severe impairment in downstream insulin signalling (Fig. 4B). Consistent with the lack of stimulation of PKCs, comparable levels of insulin-stimulated Akt and AS160 phosphorylation were observed in myoblasts incubated with CM-PA for an acute period of 1 h (Fig. S3), suggesting that a long-term incubation is required for CM-PA to induce impairment in insulin signalling. Given that G6983 prevented the long-term, deleterious effects of CM-PA on IRS1, we explored whether downstream signalling was similarly restored. Indeed, this novel and conventional PKC inhibitor abolished the negative impact of CM-PA and restored insulin-stimulated Akt (Fig. 4A) and AS160 phosphorylation (Fig. 4B) without affecting basal state phosphorylation. In contrast, the conventional PKC inhibitor G6976 did not prevent either effect of CM-PA (data not shown).

Novel PKC inhibition prevents the reduction of GLUT4myc translocation and glucose uptake caused by CM-PA

Insulin action through IRS1, Akt and AS160 stimulates glucose uptake by increasing GLUT4 glucose transporters at the plasma
membrane of muscle cells [39]. In myoblasts incubated with CM-PA, insulin-stimulated gain in surface GLUT4 myc translocation (Fig. 5A) and glucose uptake (Fig. 5B) were significantly reduced when compared with CM-BSA, confirming our previous observations [11]. Notably, the novel PKC inhibitor Go6983 prevented the CM-PA-induced insulin resistance of GLUT4 translocation and its consequent glucose uptake, such that the decreases in either parameter below the insulin-stimulated CM-BSA were no longer statistically significant (Fig. 5A and B). In contrast, Go6976 did not restore insulin action on these metabolic outcomes (Fig. 5A and B).

**Specific cytokines and chemokines in macrophage-conditioned media fail to activate novel PKC’s in muscle cells**

Several studies have shown that macrophage-derived cytokines and chemokines such as TNFα and MCP-1 can directly elicit adipose cell inflammation and insulin resistance [40,41]. Accordingly, it is likely that secreted cytokines in the conditioned media from palmitate-treated macrophages propagate inflammatory stress response and insulin resistance in muscle cells. Our previous studies showed elevated levels of TNFα in CM-PA compared to CM-BSA [11]. A more detailed analysis of this conditioned media in the present study validated that observation and further demonstrated markedly elevated levels of MCP-1 (CCL2), MIP2 (CXCL2), IP10 (CXCL10), KC (CXCL1) and CCL7 (Fig. 6A). Besides macrophage-derived factors, residual palmitate or fatty acids potentially released by the macrophages might also be present in CM-PA, even though palmitate was removed after 6 h, macrophages washed several times with PBS and fresh medium added for 12 h to collect conditioned media. To investigate these possibilities, we measured the levels of non-esterified free fatty acids (NEFA) in CM-PA. Fig. 6A (inset) shows that there was no difference in NEFA’s in CM-PA compared to CM-BSA, and moreover the levels detected fall below those reported in the literature to affect insulin action in muscle [12]. This result suggests that a protein component is likely involved in the observed defect in myoblast insulin signalling. To examine the individual impact of small protein molecules like cytokines and chemokines on activation of PKC theta and epsilon, myoblasts were incubated individually for 24 h with different concentrations (0–100 ng/ml) of the most differentially elevated cytokines and chemokines found in CM-PA compared to

---

**Figure 2. CM-PA causes activation of novel PKCθ and PKCe in L6-GLUT4myc myoblasts.** L6-GLUT4myc myoblasts were treated for 24 h with RM, CM-BSA and CM-PA. Where indicated, cells were pre-incubated for 30 min with the novel and conventional PKC inhibitor, Go6983 (1 μM) or the conventional PKC inhibitor, Go6976 (1 μM), prior to addition of CM-PA. After 24 h, cells were lysed, and equal amount of total protein from each sample were immunoblotted with specific antibodies against phospho-Thr538 PKCθ, total PKCθ (A, C and E), phospho-Ser729 PKCe, total PKCe or GAPDH (B, D and F). Representative immunoblots and densitometric quantification of three experiments are shown. Values are expressed as ratio of phosphorylated protein relative to GAPDH or total levels of respective protein. Results are mean ± SE. *Significantly different from CM-BSA, P<0.05. #Significantly different from CM-PA, P<0.05. doi:10.1371/journal.pone.0026947.g002
CM-BSA: TNFα, MIP2, IP10 and KC. Interestingly, no effect on PKCθ or PKCε phosphorylation was observed in muscle cells challenged individually with these cytokines or chemokines at indicated concentrations (Fig. 6B). We further tested the effect these cytokines and chemokines combined, using the following concentrations: TNFα (1 ng/ml), MIP2 (2 ng/ml), IP10 (1 ng/ml) and KC (10 ng/ml). However, like the individual cyto/chemokine treatments, the combination treatment also failed to elicit any rise in PKCθ and PKCε phosphorylation (Fig. 6B).
Macrophage-conditioned media causes IκBα degradation, promotes NF-kappa B nuclear translocation and elevates the expression of pro-inflammatory cytokines

Muscle can mount an autonomous inflammatory stress response to cytokines and chemokines, evinced by degradation of IκBα and the consequent activation of NF-κB dependent gene transcription through post-translational modifications of the NF-κB p65 subunit [42,43,44,45]. Consistent with this behaviour, we previously reported that CM-PA promotes IκBα degradation and elevates the expression of proinflammatory cytokines in the target myoblasts [11]. As PKCθ and PKCe have been demonstrated to act upstream of IκBα [46,47], we here hypothesized that inhibition of novel PKC’s would prevent the CM-PA-driven IκBα degradation and subsequent responses. This was found to be the case, as Go6983 prevented IκBα degradation by 81±9% (Fig. 7A) in myoblasts incubated with CM-PA for 24 h, and further significantly reduced the CM-PA dependent augmentation in MCP-1 and TNFα gene expression (Fig. 7C). Interestingly, there was no significant change in myoblast IL-6 or COX-2 gene expression in myoblasts treated with CM-PA (Fig. 7C), indicating that the effects of CM-PA are selective rather than the result of a generalized inflammatory response by the muscle cells. To directly confirm the activation of NF-κB, the phosphorylation status of its main p65 phosphorylation site, Ser536, was examined. Incubation of myoblasts with CM-PA for up to 24 h increased the cytosolic phosphorylation of NF-κB p65 at Ser536 starting at 18 h and peaking at 24 h (Fig. 7B). Further, nuclear translocation is crucial for NF-κB to exert its transcriptional effects. We found that 24 h of CM-PA treatment stimulated NF-κB nuclear translocation (Fig. 7B).

Co-silencing PKCθ and PKCe expression prevents the inhibition of insulin signalling caused by CM-PA

The results described so far revealed that palmitate-treated macrophages produce a selective array of cytokines and chemokines into a complex CM-PA, which in turn unleashes insulin resistance and inflammatory responses within muscle cells. These responses were largely ascribed to novel PKC activation, based on the alleviation of these deleterious effects by Go6983 but not Go6976. To specifically ascertain that CM-PA indeed acted through PKCθ and PKCe in its ability to alter insulin action, we aimed to silence PKCθ and PKCe expression in myoblasts via siRNA. We first validated successful PKCθ and PKCe knockdown by immunoblotting (Fig. 8A). Knockdown of either PKCθ or PKCe alone by their corresponding siRNA did not prevent the reduction in insulin-stimulated phosphorylation of Akt or AS160 induced by CM-PA (Fig. S4 A & B). Interestingly, however, knockdown of PKCθ alone enhanced by 31±6% the activating phosphorylation of PKCe observed with CM-PA (Fig. 8B). As this suggested a redundant or perhaps cooperative action of these proteins in their ability to interfere with insulin action, we enquired whether silencing both proteins together could overcome the deleterious effects of CM-PA on muscle cells. Myoblasts were transfected with a mix of siRNAs to both PKCθ and PKCe prior to challenging them with CM-PA.

Figure 4. Novel PKC inhibition prevents the decrease in insulin-stimulated phosphorylation of Akt and AS160 caused by CM-PA. L6-GLUT4myc myoblasts with or without stable expression of AS160 (L6-GLUT4myc-AS160) were incubated as described in Fig. 3, and then stimulated in the presence or absence of insulin (100 nM, 10 min). Cells were lysed, and equal amount of total protein from each sample were immunoblotted with specific antibodies against phospho-Akt (Ser473) and total Akt (A), or phospho-AS160 and total AS160 (B). Representative immunoblots and quantification of three experiments are shown. Values are expressed as ratio of phosphorylated protein relative to total levels of the respective protein. Results are the means ± SE *Significantly different from basal, P<0.05, †Significantly different from CM-BSA insulin, P<0.05.
doi:10.1371/journal.pone.0026947.g004
Proving our hypothesis, reducing PKC\(h\) protein content by 74\(+/-\)6\% (Fig. 8C) and PKC\(e\) content by 76\(+/-\)3\% (Fig. 8C) in this manner virtually abolished the inhibition in insulin-stimulated phosphorylation of Akt (Fig. 8D) and AS160 (Fig. 8E) provoked by CM-PA.

Co-silencing PKC\(h\) and PKC\(e\) expression prevents the effect of CM-PA on myoblast GLUT4\(\text{myc}\) translocation and glucose uptake

We finally sought to ascertain that the metabolic consequence of the macrophage-derived media on muscle cells was specifically mediated by PKC\(h\) and PKC\(e\). Indeed, co-silencing both PKC isoforms relieved insulin resistance, by preventing the drop in insulin stimulated GLUT4\(\text{myc}\) translocation (Fig. 9A) and glucose uptake (Fig. 9B) caused by CM-PA.

Discussion

Resident macrophages are an essential component of skeletal muscle. Positive functions of macrophages include contribution to regeneration and revascularization when in their M2 (anti-inflammatory) phenotypic polarization [1]. However, macrophages can also become M1 polarized (inflammatory), which results in inflammatory cytokine production [1]. In cell culture, products from inflammatory macrophages can confer insulin resistance to muscle cells, as in the case of fatty acid-treated RAW macrophages and L6 myoblasts [1,3,11]. However, the signalling mechanism by which macrophage-derived factors confer this negative response onto muscle cells is poorly understood. The present study shows that conditioned media from palmitate-treated macrophages (CM-PA) activates novel PKC\(h\) and PKC\(e\) that appear to be responsible for induction of pro-inflammatory gene expression, cytokine production and metabolic insulin resistance in muscle cells. Since only very low levels of NEFA’s were detected in the conditioned media and these levels did not differ between CM-PA and CM-BSA, it is unlikely that any residual fatty acid is responsible for the activation of these kinases in the muscle cells.

An interplay between fatty acids and macrophages to promote muscle cell insulin resistance is now recognized. Previous studies
Figure 6. Specific cytokines/chemokines identified in conditioned media fail to activate novel PKC’s in muscle cells. 

A, Palmitate treatment induces differential secretion of cytokines and chemokines by macrophages, revealed through a Proteome Profiler Mouse Cytokine Array. Values are expressed as the ratio of expression in CM-PA over CM-BSA, and represent the means ± SE of 2 separate experiments. NEFA levels were measured using HR series NEFA-HR kit No. 999-34691 (inset). Values are presented as the means ± SE of 3 experiments. 

B, L6-GLUT4myc myoblasts were incubated individually or in combination with different concentrations (0–100 ng/ml) of TNF-α, MIP2, IP10 or KC for 24 h. Cells were lysed, and equal amount of protein from each sample were immunoblotted with specific antibodies against phospho-PKCθ (Thr538) and phospho-PKCε (Ser729). Representative immunoblots of three experiments are shown.

doi:10.1371/journal.pone.0026947.g006
Figure 7. CM-PA promotes \( \text{I\kappa B} \alpha \) degradation, NF-kappa B nuclear translocation and induces the expression of cytokines and chemokines in myoblasts. **A**, Representative immunoblots and densitometric quantification of \( \text{I\kappa B} \alpha \) and actinin-1 after exposure of L6-GLUT4myc myoblasts to RM, CM-BSA, CM-PA, or CM-PA supplemented with Go6983 (1 \( \mu \)M). Actinin-1 served as internal loading control, and values are expressed as \( \text{I\kappa B} \alpha \) to actinin-1 ratio. Results are the mean ± SE of three independent experiments. **B**, L6-GLUT4myc myoblasts were treated for 18 or 24 h with RM, CM-BSA and CM-PA, and cytoplasmic and nuclear fractions were obtained. Cells were lysed, and equal amount of protein from each sample were immunoblotted with specific antibodies against phosphorylated NF-kappa B (pSer536) and total NF-kappa B/p65. Histone and total NF-kappa B were used as controls. Representative immunoblots and quantification of three experiments are shown. **C**, Representative densitometric quantification of transcript levels of MCP-1, TNF\( \alpha \), IL-6 and COX-2. Results are the mean ± SE of three independent experiments. *Significantly different from all other groups, \( P < 0.05 \). doi:10.1371/journal.pone.0026947.g007
have shown that conditioned medium from fatty acid-activated bone marrow-derived macrophages reduces glucose uptake in muscle cells [5]. Building on those observations, we have shown that the saturated fatty acid palmitate polarizes macrophages of the RAW264.7 cell line towards the inflammatory M1 phenotype. Moreover, CM-PA from such macrophages renders L6 muscle cells insulin-resistant [11]. In the present study, an analysis of CM-PA revealed markedly elevated levels of selective cytokines and chemokines such as TNFα, MCP-1, MIP2, IP10, and KC. Notably, TNFα, MCP-1, IP10, and KC have been shown to activate PKC’s and induce inflammatory stress via NF-κB [33,45,48,49,50]. Interestingly, we found no effect on PKCθ or PKCε phosphorylation in muscle cells challenged with these cytokines or chemokines, individually or in combination, suggesting that other macrophage-released products or their combinations are responsible for the biological effects of CM-PA. Future analysis will make it possible to dissect out whether and which other chemokines/cytokines are responsible for the insulin resistance and the inflammatory responses conferred to muscle cells.

Novel PKC’s reduce insulin signalling at the level of IRS1

PKC activation is one of several pathways leading to Ser/Thr phosphorylation of IRS proteins, mainly IRS1 [51]. Serine phosphorylation of IRS1 at a number of susceptible sites attenuates downstream insulin signalling by reducing its insulin-stimulated tyrosine phosphorylation. Studies suggest that phosphorylation of mouse IRS1 at Ser307 (Ser312 in human IRS1) is important for inflammatory stimuli-mediated inhibition of IRS1 function [20]. Here we document an increase in IRS1 Ser307 phosphorylation in muscle cells exposed to CM-PA. Activation of novel PKC’s may not mediate Ser307 phosphorylation directly, since this site is not recognized as a direct target of these kinases, yet inhibiting novel PKC’s prevented this phosphorylation. This

Figure 8. Novel PKC silencing reverses CM-PA mediated drop in insulin-stimulated phosphorylation of Akt and AS160. L6-GLUT4myc myoblasts were incubated with non-related siRNA (NR), siRNA to PKCθ (PKCθ siRNA), siRNA to PKCε (PKCε siRNA) or a combination of both (PKCθ+ε) using lipofectamine RNAi-max reagent. A and C, knockdown efficiency PKCθ and PKCε, respectively. B, L6-GLUT4myc myoblasts were treated for 24 h with RM, CM-BSA, CM-PA or CM-PA supplemented with siRNA to PKCθ (PKCθ siRNA). After 24 h, cells were lysed and each sample was immunoblotted with specific antibodies against phospho-PKCε (Ser729) and total-PKCε. Results are the means ± SE of three separate experiments *Significantly different from CM-BSA, P<0.05, #Significantly different from CM-PA, P<0.05. D and E, L6-GLUT4myc myoblasts with or without stable expression of AS160 (L6-GLUT4myc-AS160) were treated for 24 h with RM, CM-BSA, CM-PA or CM-PA supplemented with siRNA to both PKCθ and PKCε. Following 24 h treatment, cells were stimulated in the presence or absence of insulin (100 nM, 10 min). Cells were lysed, and equal amount of total protein from each sample were immunoblotted with specific antibodies against phospho-Akt (Ser473), total-Akt, phospho-AS160 and total AS-160. Results are mean ± SE of three separate experiments *Significantly different from basal, P<0.05, #Significantly different from CM-BSA insulin, P<0.05.
doi:10.1371/journal.pone.0026947.g008
finding may be explained by the action of both PKCθ and PKCe upstream of JNK [22,23,24], the kinase directly responsible for Ser307 phosphorylation [52]. In addition, CM-PA caused IRS1 phosphorylation at Ser1101, a site that can be directly phosphorylated by novel PKCθ in muscle cells and tissue [20]. Because Ser1101 phosphorylation has been consequently linked to reduced IRS-1 tyrosine phosphorylation and downstream insulin signalling [20], we hypothesized that PKCθ may be directly responsible for the reduction in IRS1 signalling in muscle cells challenged with CM-PA. Indeed, we report that chemical inhibition of novel PKC’s or silencing gene expression of PKCθ and PKCe prevents both IRS1 Ser1101 phosphorylation and tyrosine phosphorylation.

Besides IRS1, CM-PA treatment of myoblasts reduced the insulin-dependent tyrosine phosphorylation of the insulin receptor. More than one mechanism may be responsible for this effect. Pro-inflammatory cytokine administration to muscle cells increases the activity of protein-tyrosine phosphatase 1B (PTP1B) that dephosphorylates phosphotyrosine residues in the insulin receptor [53]. It is therefore possible that inflammatory factors present in CM-PA contribute to the observed reduction in insulin receptor tyrosine phosphorylation via phosphatase like PTP1B. Serine phosphorylation of IRS1, via a feedback loop, might also inhibit insulin receptor tyrosine kinase activity [54], which may explain the decrease in insulin receptor tyrosine phosphorylation observed with CM-PA (however, this would not be mediated by IRS1 phosphorylation on Ser307 or Ser1101, see below).

**CM-PA acts through novel PKC’s to reduce Akt and AS160 responses to insulin**

Down-stream of IRS1, activation of Akt by insulin requires hierarchical phosphorylation on two residues, Thr308 and Ser473 [55]. CM-PA treatment of myoblasts resulted in a small reduction in insulin-stimulated phosphorylation of Akt at Ser473. It is possible that this mild reduction in Akt may not suffice per se to impose GLUT4 resistance downstream, since studies show that much greater reductions are required for this metabolic outcome [55,56,57]. However, the more marked inhibition of AS160 phosphorylation observed with CM-PA reveals an amplification of...
insulin resistance and may be the direct cause of the impaired insulin-stimulated GLUT4 translocation and glucose uptake. Like novel PKC's, activation of conventional PKC isoforms (α, βI, βII, and γ) is associated with inhibition of early steps in the insulin signalling cascade [50,59]. As Go6983 (novel and conventional PKC inhibitor) but not Go6976 (specific conventional PKC inhibitor), restored insulin signalling through the IRS1, Akt and AS160 leading to normalization of muscle glucose uptake, our findings suggest that the CM-PA-induced block in insulin action downstream of the insulin receptor is mediated by novel PKC's, likely PKCθ and ε. Failure of Go6983 to prevent the drop in insulin receptor tyrosine phosphorylation advocates that the effect of CM-PA on the insulin receptor is mediated by a mechanism not involving novel PKC's. Further, since Go6983 restored the impairment of downstream insulin signalling in attendance of reduced insulin receptor tyrosine phosphorylation, it can be concluded that the partial alteration in insulin receptor function has no consequence on downstream insulin action.

**CM-PA elicits inflammatory responses in muscle cells mediated by novel PKC's**

Activation of the NF-κB signalling cascade is pivotal to inflammatory responses and insulin resistance in muscle cells [60]. In the resting state, IκBα proteins restrict the NF-κB dimer in the cytoplasm. Phosphorylation of IκBα by IκB kinase induces its proteasomal degradation, releasing the NF-κB heterodimer to translocate to the nucleus and regulate proinflammatory gene expression [60]. Interestingly, we found that Go6983 prevented the IκBα degradation and induction of inflammatory cytokine/chemokine (TNFα and MCP1) gene expression in muscle cells caused by CM-PA. Hence we propose that the inflammatory response of muscle cells challenged by CM-PA is mediated through novel PKC's. These results add to a growing number of studies showing involvement of novel PKC's in cell autonomous inflammation: In pancreatic acinar cells, TNFα activates novel PKCθ and ε to regulate NF-κB mediated gene transcription [33]. In the human eosinophilic leukemia cell line EoL-1, MCP-1 activates PKCθ to promote an NF-κB mediated inflammatory response [45]. Direct treatment of C2C12 muscle cells with palmitate elevates IL-6 gene expression via activation of NF-κB and PKC and concomitantly reduces insulin signalling [61]. Palmitate also activates NF-κB and promotes pro-inflammatory cytokine expression by a mechanism involving novel PKC's in C2C12 and L6 skeletal muscle cells [16,18]. Hence, fatty acids and cytokines alike, such as those present in CM-PA, activate novel PKC's in muscle cells to in turn cause insulin resistance.

**Identification of PKCθ and PKCe as the mediators of CM-PA-induced inflammation and insulin resistance in muscle cells**

A major goal of this study was to identify the PKC isoforms responsible for CM-PA-induced insulin resistance. Because...
isoform specific pharmacological inhibitors are not currently available for most PKC's, the most convincing way to demonstrate a causative role for a particular isoform in the generation of insulin resistance is to compare effects in cells transfected with isoform-specific siRNA sequences. Co-silencing both PKCθ and ε by RNA interference (but not individual PKC silencing) prevented the inflammatory response and restored insulin sensitivity to CM-PA-treated muscle cells. These results suggest that among novel PKC's, the PKCθ and ε isoforms may be critical for CM-PA-induced inflammation and insulin resistance. Further, single knockdown of PKCθ is compensated by increased activation of PKCε in CM-PA treated myoblasts, suggesting that an additional role for PKCε in muscle cells is unmasked.

PKCθ and PKCε involvement in insulin resistance in vivo
PKCθ and PKCε have emerged as strong candidates for mediating lipid-induced insulin resistance. In mice, PKCθ activation prevents lipid infusion-induced defects in insulin signalling and glucose transport in skeletal muscle [62]. In addition, knockout of each PKCθ or PKCε genes in mice enhances insulin signalling and glucose tolerance, and protect against fat induced insulin resistance [62,63]. This collective evidence points to a pivotal role for these novel PKC's in insulin resistance in vivo. Our results add a new dimension to this connection, by suggesting the possibility that, in the context of high fat diets or fatty acid infusion, cytokines are released by pro-inflammatory macrophages (activated by adipose tissue-derived or circulating fatty acids), which in turn impinge on muscle, to activate PKCθ and PKCε in muscle cells. We speculate that activation of these novel PKC isoforms may be a consequence of diacylglycerol formation in response to pro-inflammatory factors present in CM-PA, since there is precedent that cytokine treatment promotes diacylglycerol formation in muscle cells [34]. Finally, our findings reveal that silencing either PKC isoform alone would not be a suitable pharmacological strategy to overcome inflammation and insulin resistance in the context of high fat diets, and instead suggest that combined inhibition of both PKCθ and ε would be far more beneficial.

In summary, we report that that the block in muscle insulin action brought about by CM-PA is mediated by the novel PKCθ and PKCε. Both isoforms, directly and/or via the stress kinase JNK inhibit insulin signalling at the level of IRS1, Akt and AS160 lowering insulin-dependent GLUT4 translocation and glucose uptake (Fig. 10). CM-PA treatment of skeletal muscle cells also induces pro-inflammatory gene expression through the activation of PKCθ/ε-NF-κB axis, which likely contributes further to the decline in insulin action (Fig. 10). In the future, we aim to identify which of the various inputs of PKC's dominates in mediating the CM-PA-induced insulin resistance in muscle cells. Overall, this study reestablishes the participation of macrophages as a relay in the action of fatty acids on muscle cells, and further identifies PKCθ and PKCε as key elements in the inflammatory and insulin resistance responses of muscle cells to macrophage products. Furthermore, it portrays these PKC isoforms as a potential joint target for the treatment of fatty acid-induced, inflammation-linked insulin resistance.

Supporting Information

Figure S1  Acute incubation of muscle cells with CM-PA fails to activate novel PKC's. Macrophages were treated with BSA alone or 500 μM palmitate/1% BSA in culture medium for 6 h, then washed several times with PBS, and fresh medium was added. After 12 h, conditioned media (CM-BSA, CM-PA) were collected, centrifuged, and added to myoblast cultures for 1 h. As a control, myoblasts were simultaneously incubated with exogenous TNF-alpha (10 ng/ml for 1 h or 24 h). Lysates were prepared from all conditions and equal amounts of protein from each sample were immunoblotted with specific antibodies against phospho-PKCθ (Thr538) and phospho-PKCε (Ser729). Representative gels of two experiments are shown. (TIF)

Figure S2  Novel PKC inhibition does not prevent the drop in insulin-stimulated tyrosine phosphorylation of the insulin receptor observed with CM-PA. L6-GLUT4myc cells expressing the human insulin receptor were treated for 24 h with RM, CM-BSA and CM-PA. Where indicated, cells were preincubated for 30 min with the novel and conventional PKC inhibitor, Go6983 (1 μM), prior to addition of CM-PA. Cells were lysed and equal amount of total protein from each sample were immunoblotted with anti-pY or anti-IR β-subunit either directly or following stimulation with insulin (100 nM for 10 min). Representative gels of two experiments are shown. (TIF)

Figure S3 Short-term incubation of muscle cells with CM-PA does not impact on insulin-stimulated phosphorylation of Akt and AS160. Macrophages were treated with BSA alone or 500 μM palmitate/1% BSA in culture medium for 6 h, and then washed several times with PBS, and fresh medium was added. After 12 h, conditioned media (CM-BSA, CM-PA) were collected, centrifuged, and added to myoblast cultures for 1 h, then myoblasts were serum-starved and pretreated with or without insulin (100 nM, 20 min) as usual. As a control, myoblasts were simultaneously incubated with exogenous TNF-alpha (10 ng/ml for 1 h). Lysates were prepared and equal amount of protein from each sample were immunoblotted with specific antibodies against phospho-Akt (Ser473) and phospho-AS160. Representative gels of two experiments are shown. (TIF)

Figure S4 Individually silencing novel PKCθ or ε does not restore insulin sensitivity in CM-PA treated myoblasts. L6-GLUT4myc myoblasts were treated for 24 h with RM, CM-BSA, CM-PA, or CM-PA supplemented with siRNA to PKCθ or PKCε (100 nM each). Following 2 h of serum starvation, myoblasts were stimulated in the presence or absence of insulin (100 nM for 20 min). Cells were lysed, and equal amount of total protein from each sample were immunoblotted with specific antibodies against phospho-Akt (Ser473) and total Akt (A); or phospho-AS160 and total AS-160 (B). Representative immunoblots of two experiments are shown. (TIF)

Acknowledgments

We thank Dr. Philip J. Bilan for advice during the course of this study and Zhi Liu for technical support

Author Contributions

Conceived and designed the experiments: AK GK. Performed the experiments: GK LNF. Analyzed the data: GK LNF AK FA. Contributed reagents/materials/analysis tools: AK LNF. Wrote the paper: GK LNF AK.
Novel PKC's in Muscle Insulin Resistance

References

1. Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219–246.
2. Heilbronn LK, Campbell LV (2008) Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 14: 1225–1230.
3. Lameng CN, Deyoung SM, Sabiel AR (2007) Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. J Physiol Pharmacol 58: 27–46.
4. Weber SP, McCann D, Desai M, Rosenbaum M, Leibl RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796–1808.
5. Deyoung SM, Deyoung CN, Bodzin JL, Sabiel AR (2007) Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56: 16–23.
6. Lameng CN, Bodzin JL, Sabiel AR (2007) Obesity induces a phenotypic switch in murine tissue macrophage polarization. J Clin Invest 117: 175–184.
7. Vetter R, Milan G, Frauenfelder SW, Maena S, De Coppi P, et al. (2007) The Origin of Intermuscular Adipose Tissue and Its Pathophysiologial Implications. Am J Physiol Endocrinol Metab 297: E907–E910.
8. Heveren AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadhyay G, et al. (2007) Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 117: 1658–1669.
9. Sznolikovsz V, Bilan PJ, Schertzer JD, Antonescu CN, Filip A (2009) Palmitate induces PKC-theta and phosphatidylinositol-3-kinase-activated macrophages evoking contrasting responses in insulin cells in muscle. Am J Physiol Endocrinol Metab 297: E36–E47.
10. Dimopoulos N, Watson M, Sakamoto K, Huns H (2006) Differential effects of palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells. Biochem J 399: 473–481.
11. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, et al. (2007) High fat diet induces tumor necrosis factor-alpha expression in C2C12 skeletal muscle cells by activating PKC isoforms therein. Cell Physiol Biochem 16: 217–228.
12. Huang C, Thirone AC, Huang X, Klip A (2005) Differential contribution of PKC isoforms in FFA induced defects in insulin signaling. Mol Cell Endocrinol 279: 45304–45307.
13. Kellerer M, Mushack J, Mischak H, Haring HU (1997) Protein kinase C (PKC) epsilon overexpression in skeletal muscle precedes the onset of insulin resistance. J Biol Chem 272: 35279–35292.
14. Varma V, Yao-Borengasser A, Rasouli N, Nolen GT, Phanavanh B, et al. (2009) Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am J Physiol Endocrinol Metab 296: E1300–1310.
15. Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, et al. (2000) NAK is an IkappaB kinase-activating kinase. Nature 404: 778–782.
16. Schenk S, Saberi M, Olefsky JM (2006) Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 117: 2992–3002.
17. Austin RL, Rane A, Bouzekri K, Zierath JR, Krook A (2009) sRNA-mediated reduction of inhibitor of nuclear factor-κB kinase activity prevents high fat diet-associated glucose intolerance. J Biol Chem 284: 22497–22501.
18. Schutze S, Berkovic D, Tomsing O, Unger C, Kronke M (1991) Tumor necrosis factor induces rapid production of 12β-fatty acylglycerol by a phosphatidylcholine-specific phospholipase C. J Exp Med 174: 973–981.
19. Parekh D, Ziegler W, Yonezawa K, Hara K, Parker JT (1999) Mammalian TOR controls one of two kinase pathways acting upon nPKCdelta and nPKCepsilon. J Biol Chem 274: 3475–3476.
20. Schenk S, Saberi M, Olefsky JM (2006) Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 117: 2992–3002.
21. Odegaard JI, Chawla A (2008) Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab 4: 619–628.
22. Schutze S, Berkovic D, Tomsing O, Unger C, Kronke M (1991) Tumor necrosis factor induces rapid production of 12β-fatty acylglycerol by a phosphatidylcholine-specific phospholipase C. J Exp Med 174: 973–981.
23. Parekh D, Ziegler W, Yonezawa K, Hara K, Parker JT (1999) Mammalian TOR controls one of two kinase pathways acting upon nPKCdelta and nPKCepsilon. J Biol Chem 274: 3475–3476.
24. Schutze S, Berkovic D, Tomsing O, Unger C, Kronke M (1991) Tumor necrosis factor induces rapid production of 12β-fatty acylglycerol by a phosphatidylcholine-specific phospholipase C. J Exp Med 174: 973–981.
25. Parekh D, Ziegler W, Yonezawa K, Hara K, Parker JT (1999) Mammalian TOR controls one of two kinase pathways acting upon nPKCdelta and nPKCepsilon. J Biol Chem 274: 3475–3476.
26. Kellner M, Mihack J, Haring HU (1997) Protein kinase C (PKC) epsilon enhances the inhibitory effect of TNF alpha on insulin signaling in H9c2 cells. FEBS Lett 410: 119–122.
27. Uyama A, Yawo-KL, Wang Q, Ebina Y, Klip A (1999) GLUT-4myc ectopic expression in L6 myoblasts generates a GLUT-4-specific pool conferring insulin sensitivity. Am J Physiol 277: E572–578.
28. Niu W, Huang C, Nawaz Z, Levy M, Somwar R, et al. (2003) Maturation of the regulation of GLUT4 activity by p38 MAPK during L6 cell myogenesis. J Biol Chem 278: 17953–17962.
29. Wang Q, Khayat Z, Kushi E, Ebina Y, Klip A (1998) GLUT4 translocation by insulin in intact muscle cells: detection by a fast and quantitative assay. FEBS Lett 427: 193–197.
30. Ji YY, Liu JT, Liu N, Wang ZD, Liu CH (2009) PPARalpha activator Rifabutin inhibits insulin signaling by phosphorylating IRS1 at Ser(1101). J Biol Chem 284: 22497–22501.
31. Xu ZB, Chauhairy D, Olland S, Wolfart C, Szwierski R, et al. (2004) Catalytic domain crystal structure of protein kinase C-theta (PKCTheta). J Biol Chem 279: 50401–50409.
32. Schutze S, Berkovic D, Tomsing O, Unger C, Kronke M (1991) Tumor necrosis factor induces rapid production of 12β-fatty acylglycerol by a phosphatidylcholine-specific phospholipase C. J Exp Med 174: 973–981.
33. Schenk S, Saberi M, Olefsky JM (2006) Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 117: 2992–3002.
34. Schutze S, Berkovic D, Tomsing O, Unger C, Kronke M (1991) Tumor necrosis factor induces rapid production of 12β-fatty acylglycerol by a phosphatidylcholine-specific phospholipase C. J Exp Med 174: 973–981.
35. Schutze S, Berkovic D, Tomsing O, Unger C, Kronke M (1991) Tumor necrosis factor induces rapid production of 12β-fatty acylglycerol by a phosphatidylcholine-specific phospholipase C. J Exp Med 174: 973–981.
36. Schutze S, Berkovic D, Tomsing O, Unger C, Kronke M (1991) Tumor necrosis factor induces rapid production of 12β-fatty acylglycerol by a phosphatidylcholine-specific phospholipase C. J Exp Med 174: 973–981.
37. Schutze S, Berkovic D, Tomsing O, Unger C, Kronke M (1991) Tumor necrosis factor induces rapid production of 12β-fatty acylglycerol by a phosphatidylcholine-specific phospholipase C. J Exp Med 174: 973–981.
38. Schutze S, Berkovic D, Tomsing O, Unger C, Kronke M (1991) Tumor necrosis factor induces rapid production of 12β-fatty acylglycerol by a phosphatidylcholine-specific phospholipase C. J Exp Med 174: 973–981.
receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275: 9047–9054.

53. Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro C, Rondinone CM, Valverde AM, et al. (2007) Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance. Diabetes 56: 404–413.

54. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94: 1543–1549.

55. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, et al. (1999) Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol Cell Biol 19: 4008–4018.

56. Bilan PJ, Samokhvalov V, Koshkina A, Schertzer JD, Samaan MC, et al. (2009) Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Arch Physiol Biochem 115: 176–190.

57. Hoehn KL, Hohnen-Behrens C, Cederberg A, Wu LE, Turner N, et al. (2008) IRS1-independent defects define major nodes of insulin resistance. Cell Metab 7: 421–433.

58. Chin JE, Liu F, Roth RA (1994) Activation of protein kinase C alpha inhibits insulin-stimulated tyrosine phosphorylation of insulin receptor substrate-1. Mol Endocrinol 8: 51–58.

59. Kawai Y, Ishizuka T, Kajita K, Miura A, Ishizawa M, et al. (2002) Inhibition of PKCbeta improves glucocorticoid-induced insulin resistance in rat adipocytes. IUBMB Life 54: 365–370.

60. Mourkioti F, Rosenhal N (2008) NF-kappaB signaling in skeletal muscle: prospects for intervention in muscle diseases. J Mol Med 86: 747–759.

61. Jove M, Planavila A, Laguna JC, Vazquez-Carrera M (2005) Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kappaB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells. Endocrinology 146: 3087–3095.

62. Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashinori T, et al. (2004) PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest 114: 823–827.

63. Frangissadakis G, Burchfield JG, Narazimhan S, Cooney GJ, Leitges M, et al. (2009) Diverse roles for protein kinase C delta and protein kinase C epsilon in the generation of high-fat-diet-induced glucose intolerance in mice: regulation of lipogenesis by protein kinase C delta. Diabetologia 52: 2616–2620.